vs
Side-by-side financial comparison of Enphase Energy (ENPH) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Enphase Energy is the larger business by last-quarter revenue ($282.9M vs $168.4M, roughly 1.7× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -20.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -3.4%).
Enphase Energy, Inc. is an American energy technology company headquartered in Fremont, California, that develops and manufactures solar micro-inverters, battery energy storage, and EV charging stations primarily for residential customers. Enphase was established in 2006 and is the first company to successfully commercialize solar micro-inverters, which convert the direct current (DC) power generated by solar panels into grid-compatible alternating current (AC) for use or export.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ENPH vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $282.9M | $168.4M |
| Net Profit | $-7.4M | — |
| Gross Margin | 35.5% | — |
| Operating Margin | 54.0% | 50.6% |
| Net Margin | -2.6% | — |
| Revenue YoY | -20.6% | 143.7% |
| Net Profit YoY | -124.9% | — |
| EPS (diluted) | $-0.06 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $282.9M | — | ||
| Q4 25 | $343.3M | $168.4M | ||
| Q3 25 | $410.4M | $87.3M | ||
| Q2 25 | $363.2M | $82.4M | ||
| Q1 25 | $356.1M | $65.0M | ||
| Q4 24 | $382.7M | $69.1M | ||
| Q3 24 | $380.9M | $51.6M | ||
| Q2 24 | $303.5M | $73.8M |
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $38.7M | — | ||
| Q3 25 | $66.6M | $-31.3M | ||
| Q2 25 | $37.1M | $-12.7M | ||
| Q1 25 | $29.7M | $-40.5M | ||
| Q4 24 | $62.2M | — | ||
| Q3 24 | $45.8M | $-29.5M | ||
| Q2 24 | $10.8M | $-61.9M |
| Q1 26 | 35.5% | — | ||
| Q4 25 | 44.3% | — | ||
| Q3 25 | 47.8% | — | ||
| Q2 25 | 46.9% | — | ||
| Q1 25 | 47.2% | — | ||
| Q4 24 | 51.8% | — | ||
| Q3 24 | 46.8% | — | ||
| Q2 24 | 45.2% | — |
| Q1 26 | 54.0% | — | ||
| Q4 25 | 6.5% | 50.6% | ||
| Q3 25 | 16.1% | -11.4% | ||
| Q2 25 | 10.2% | 8.6% | ||
| Q1 25 | 9.0% | -34.0% | ||
| Q4 24 | 14.3% | -6.4% | ||
| Q3 24 | 13.1% | -31.0% | ||
| Q2 24 | 0.6% | 3.5% |
| Q1 26 | -2.6% | — | ||
| Q4 25 | 11.3% | — | ||
| Q3 25 | 16.2% | -35.9% | ||
| Q2 25 | 10.2% | -15.4% | ||
| Q1 25 | 8.3% | -62.2% | ||
| Q4 24 | 16.2% | — | ||
| Q3 24 | 12.0% | -57.2% | ||
| Q2 24 | 3.6% | -83.9% |
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.29 | $0.32 | ||
| Q3 25 | $0.50 | $-0.16 | ||
| Q2 25 | $0.28 | $-0.06 | ||
| Q1 25 | $0.22 | $-0.21 | ||
| Q4 24 | $0.46 | $-0.14 | ||
| Q3 24 | $0.33 | $-0.15 | ||
| Q2 24 | $0.08 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.5M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $-302.0M |
| Total Assets | $2.7B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $497.5M | — | ||
| Q4 25 | $1.5B | $167.9M | ||
| Q3 25 | $1.5B | $92.4M | ||
| Q2 25 | $1.5B | $86.1M | ||
| Q1 25 | $1.5B | $114.6M | ||
| Q4 24 | $1.6B | $144.8M | ||
| Q3 24 | $1.8B | $144.7M | ||
| Q2 24 | $1.6B | $189.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $-302.0M | ||
| Q3 25 | $995.0M | $-451.4M | ||
| Q2 25 | $880.6M | $-433.5M | ||
| Q1 25 | $810.7M | $-426.2M | ||
| Q4 24 | $833.0M | $-388.7M | ||
| Q3 24 | $931.4M | $-370.2M | ||
| Q2 24 | $884.5M | $-344.2M |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $3.5B | $465.9M | ||
| Q3 25 | $3.3B | $364.0M | ||
| Q2 25 | $3.2B | $347.1M | ||
| Q1 25 | $3.1B | $324.0M | ||
| Q4 24 | $3.2B | $343.8M | ||
| Q3 24 | $3.3B | $314.1M | ||
| Q2 24 | $3.2B | $352.3M |
| Q1 26 | — | — | ||
| Q4 25 | 1.11× | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.48× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.47× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $102.9M | $45.2M |
| Free Cash FlowOCF − Capex | $83.0M | — |
| FCF MarginFCF / Revenue | 29.3% | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $145.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $102.9M | — | ||
| Q4 25 | $47.6M | $45.2M | ||
| Q3 25 | $13.9M | $-4.3M | ||
| Q2 25 | $26.6M | $-31.4M | ||
| Q1 25 | $48.4M | $-22.6M | ||
| Q4 24 | $167.3M | $-35.0M | ||
| Q3 24 | $170.1M | $-35.3M | ||
| Q2 24 | $127.1M | $-7.2M |
| Q1 26 | $83.0M | — | ||
| Q4 25 | $37.8M | — | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $18.4M | — | ||
| Q1 25 | $33.8M | — | ||
| Q4 24 | $159.2M | — | ||
| Q3 24 | $161.6M | $-35.5M | ||
| Q2 24 | $117.4M | $-7.3M |
| Q1 26 | 29.3% | — | ||
| Q4 25 | 11.0% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.5% | — | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 42.4% | -68.7% | ||
| Q2 24 | 38.7% | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 0.0% | ||
| Q3 25 | 2.0% | 0.0% | ||
| Q2 25 | 2.3% | 0.0% | ||
| Q1 25 | 4.1% | 0.0% | ||
| Q4 24 | 2.1% | 0.0% | ||
| Q3 24 | 2.2% | 0.3% | ||
| Q2 24 | 3.2% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.23× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 2.69× | — | ||
| Q3 24 | 3.72× | — | ||
| Q2 24 | 11.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENPH
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
